Pharmaceutical Outsourcing covers news of importance to the contract services segment of the pharmaceutical industry.
Collected from the most trusted on-line resources, these news stories are chosen and published here based on their relevance to the pharmaceutical industry.
Topics of interest typically include: mergers and acquisitions, service additions, new capabilities, personnel changes, news from the FDA and other international regulatory and standard-setting agencies, and new outsourcing contracts and deals.
If you are looking to stay up-to-date with the news in your industry, this resource is vital for your industry knowledge.
Cobra Biologics has signed an agreement with AstraZeneca to manufacture the adenovirus vector-based COVID-19 vaccine candidate AZD1222.
read more
Monday, February 13, 2012
Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals, announces the appointment of three non-executive directors to Cobra Biologics’ board, and two business development managers tasked with driving ...
read more
Cobra Biologics and Symbiosis Pharmaceutical Services announced the successful completion of their collaboration to develop synergistic and world leading capabilities.
read more
Wednesday, February 21, 2018
Cobra Biologics and Symbiosis Pharmaceutical Services announced that they have been awarded a 16-month collaborative grant of £1.9m ($2.5m) from Innovate UK.
read more
Monday, November 26, 2018
Cobra Biologics has won a £1.5m shared grant from Innovate UK, the United Kingdom’s innovation agency.
read more
Cobra Biologics and the Karolinska Institutet have been awarded €3 million emergency funding by Horizon 2020 for phase I testing of a DNA vaccine against COVID-19.
read more
Cobra Biologics has successfully produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01, which is being developed for the treatment of drug-resistant focal epilepsy.
read more
Cobra has successfully produced and supplied two further DNA plasmids for the production of CombiGene’s gene therapy drug candidate CG01.
read more
Wednesday, August 19, 2020
Cobra Biologics CombiGene announced Cobra has successfully produced master cell banks for the three plasmids used as starting material for CombiGene’s gene therapy CG01.
read more
Cobra Biologics Ltd, the international clinical and commercial manufacturer of biologics and pharmaceuticals and Vaccibody AS, a biotechnology company developing the next generation of vaccines against cancer and chronic infections, today announce an...
read more
Cobra Biologics Ltd, the international clinical and commercial manufacturer of biologics and pharmaceuticals and Recopharma, a biotechnology company developing ophthalmic products, today announce an agreement to supply a human Fc fusion protein using...
read more
Cobra Biologics Ltd, the International clinical and commercial manufacturer of biologics and pharmaceuticals and Novolytics, a biotechnology company developing anti-infective products, today announce a breakthrough in the development of two ...
read more
Cobra Biologics, the international clinical and commercial manufacturer of biologics and pharmaceuticals and KAHR Medical Limited, that develops novel drugs based on the Signal Converter Proteins (SCP) technology for the treatment of cancer and ...
read more
Cobra Biologics, a leading contract manufacturer of clinical and commercial scale biologics and pharmaceuticals, and targeted cancer therapy company BioCancell have announced an agreement to manufacture BioCancell’s BC-821 cancer drug for clinical ...
read more
FDA is alerting health care professionals to a voluntary recall of all non-expired products marketed as sterile made by Coastal Meds due to visible particles in some of the drug vials for injection.
read more